Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Antibodies to COVID-19 fall by half in less than 90 days, and antibody levels peak lower and fall faster in younger adults, an ongoing study of staff at Oxford University Hospitals NHS Foundation Trust has revealed.

Swab testing in the OUH laboratories © Jon Lewis, Oxford Hospitals Charity

The findings, published on the pre-print server medRxiv, also showed that antibodies to the virus last longer in people who have had symptoms, and fade quicker in those who were asymptomatic.

The paper – ‘The duration, dynamics and determinants of SARS-CoV-2 antibody responses in individual healthcare workers’ – presents six months of data from a longitudinal seroprevalence study of 3,217 OUH healthcare workers who have attended more than once for antibody testing.

They were among some 10,000 staff across OUH’s four hospitals who have been tested both for presence of the virus responsible for COVID-19 and antibodies to the virus, to give an accurate picture of who among the OUH workforce had had coronavirus infection. The study is a major collaboration between OUH and the University of Oxford, with support from the NIHR Oxford Biomedical Research Centre.

By measuring antibody responses in the same healthcare workers for up to six months, the researchers could follow what happens to antibody levels over time and how this varied between different people.

The full story is available on the NIHR Oxford Biomedical Research Centre website

It is also featured on the Nuffield Department of Population Health website

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.